Lynne Fahey McGrath is Director at Alzamend Neuro, Inc. (ALZN). They have made 3 open-market trades across 1 company since 2022, most recently 2025-10-23.
CIK 0001866270
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $4K since 2023, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ALZN | 25 | $39 |
Shares reported on the most recent Form 4, priced at the 2025-10-24 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.